A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome.
Maksoud, Rebekah, Balinas, Cassandra, Holden, Sean et al. · Journal of translational medicine · 2021 · DOI
Quick Summary
This review looked at whether special supplements that target the energy-producing parts of cells (mitochondria) might help ME/CFS patients feel less fatigued. The researchers searched for published studies testing these supplements in ME/CFS patients and found 9 studies. About two-thirds of these studies showed some improvement in fatigue, but the overall evidence isn't strong enough yet to say these supplements definitely work.
Why It Matters
This review is important because ME/CFS lacks approved treatments and a clear understanding of its underlying mechanisms. By systematically evaluating whether mitochondrial-targeting supplements help, this work helps both patients and clinicians understand what evidence currently exists and guides future research priorities in this understudied area.
Observed Findings
Six of nine studies reported improvements in fatigue levels following mitochondrial-targeting nutraceutical interventions
Studies also measured secondary outcomes including biochemical markers, psychological parameters, and quality of life measures
Significant heterogeneity existed across studies in design, intervention type, sample sizes, and outcome assessment methods
The review covered interventions published over a 25-year period (1995–2020)
Inferred Conclusions
There is currently insufficient evidence to recommend mitochondrial-targeting nutraceuticals as an established treatment for ME/CFS
While some studies showed promise, methodological limitations and inconsistencies prevent definitive conclusions about effectiveness
Future well-designed, adequately powered trials are needed to clarify both mitochondrial involvement in ME/CFS pathology and the true effects of these interventions
Remaining Questions
Which specific nutraceuticals, if any, are most effective for reducing ME/CFS fatigue and other symptoms?
How do mitochondrial dysfunctions specifically contribute to ME/CFS pathophysiology, and how can this be reliably measured?
What study design, outcome measures, and patient populations would best establish whether mitochondrial-targeting interventions have clinical benefit?
What This Study Does Not Prove
This review does not prove that mitochondrial dysfunction causes ME/CFS or that these supplements are effective treatments. The mixed results across studies and acknowledged methodological weaknesses mean we cannot yet conclude whether any particular nutraceutical reliably reduces fatigue. Positive findings in some studies do not establish causation or demonstrate that mitochondrial targeting is the mechanism of any benefit.